Q-omics provides the consensus-scored PIK3CA profile across patient tissues and cancer cell-line models. PIK3CA expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PIK3CA is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, PIK3CA RNA expression shows 20,965 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where PIK3CA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PIK3CA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PIK3CA survival associations across molecular data types. PIK3CA RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PIK3CA RNA expression–survival associations across cancer types. High PIK3CA expression shows unfavorable associations in ACC, BLCA, PAAD, LIHC and UCEC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PIK3CA RNA expression.
This table summarizes PIK3CA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PIK3CA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PIK3CA shows lower tumor expression in BRCA and UCEC and higher tumor expression in HNSC, LUSC, LIHC and CHOL. The HNSC box plot shows higher PIK3CA RNA expression in tumor versus normal tissue (log2 FC = +1.137, t-test p < 0.001).
This table shows molecular features associated with PIK3CA in patient tissues and cancer cell lines. In patient samples, PIK3CA shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PIK3CA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
